Table 1. Sensitivity (LC50) of human... | Rockefeller University Press

Table 1.

Sensitivity (LC50) of human breast cell lines to chemotherapeutic drugs

Cell line	Receptor status	Elevated MYC	Paclitaxel	Doxorubicin
			µM	µM
MDA-MB-231	TN	Yes	0.82	0.73
HCC3153	TN	Yes	0.15	>5.0
BT549	TN	Yes	0.14	0.61
MCF10A^MYC	TN	Yes	0.21	0.77
SUM149	TN	Yes	0.67	4.6
HCC1428	RP	No	>5.0	0.72
UACC812	RP	No	1.3	0.85
T47D	RP	No	0.06	0.37
LY2	RP	No	>5.0	0.55
SKBR3	RP	Intermediate	0.05	0.91

Cell line	Receptor status	Elevated MYC	Paclitaxel	Doxorubicin
			µM	µM
MDA-MB-231	TN	Yes	0.82	0.73
HCC3153	TN	Yes	0.15	>5.0
BT549	TN	Yes	0.14	0.61
MCF10A^MYC	TN	Yes	0.21	0.77
SUM149	TN	Yes	0.67	4.6
HCC1428	RP	No	>5.0	0.72
UACC812	RP	No	1.3	0.85
T47D	RP	No	0.06	0.37
LY2	RP	No	>5.0	0.55
SKBR3	RP	Intermediate	0.05	0.91

MYC protein expression by quantitative Western blotting in triple-negative (TN) and receptor-positive (RP) cell lines is indicated. No correlation between elevated MYC expression and sensitivity to paclitaxel or doxorubicin was observed (two-tailed Student’s t test).

[ViewLarge]